Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Spreafico

Showing results (41-50 of 186) with videos related to

Pageof 19
Sort By:
The Laryngoscope|June 3, 2024
Nodal Metastases in Stage 3 Head and Neck Melanoma: Patterns of Metastases and Patterns of FailureSharon Tzelnick, John R de Almeida, Christopher M K L Yao, et al.
Cancers|July 29, 2023
Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to ImmunotherapyMaysa Vilbert, Erica C Koch, April A N Rose, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2023
Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patientsKirsty Taylor, Jinfeng Zou, Marcos Magalhaes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2Paul J Hesketh, Kari Chansky, Antoinette J Wozniak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 4, 2011
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitorsChiara Lazzari, Anna Spreafico, Angela Bachi, et al.
JCO Precision Oncology|April 7, 2023
Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical TrialsEnrique Sanz-Garcia, Sofia Genta, Xiaoxi Chen, et al.
F1000Research|December 10, 2020
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometryMilena Music, Marco Iafolla, Antoninus Soosaipillai, et al.
Molecular Oncology|April 24, 2012
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancerJohn J Arcaroli, Rebecca W Powell, Marileila Varella-Garcia, et al.
Investigational New Drugs|April 12, 2018
A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumoursKyaw L Aung, Anthony B El-Khoueiry, Karen Gelmon, et al.
Clinical Colorectal Cancer|August 21, 2021
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal CancerKanan Alshammari, Kyaw L Aung, Tong Zhang, et al.
Pageof 19

Showing results (41-50 of 186) with videos related to

Sort By:
Pageof 19
The Laryngoscope|June 3, 2024
Nodal Metastases in Stage 3 Head and Neck Melanoma: Patterns of Metastases and Patterns of FailureSharon Tzelnick, John R de Almeida, Christopher M K L Yao, et al.
Cancers|July 29, 2023
Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to ImmunotherapyMaysa Vilbert, Erica C Koch, April A N Rose, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2023
Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patientsKirsty Taylor, Jinfeng Zou, Marcos Magalhaes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2Paul J Hesketh, Kari Chansky, Antoinette J Wozniak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 4, 2011
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitorsChiara Lazzari, Anna Spreafico, Angela Bachi, et al.
JCO Precision Oncology|April 7, 2023
Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical TrialsEnrique Sanz-Garcia, Sofia Genta, Xiaoxi Chen, et al.
F1000Research|December 10, 2020
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometryMilena Music, Marco Iafolla, Antoninus Soosaipillai, et al.
Molecular Oncology|April 24, 2012
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancerJohn J Arcaroli, Rebecca W Powell, Marileila Varella-Garcia, et al.
Investigational New Drugs|April 12, 2018
A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumoursKyaw L Aung, Anthony B El-Khoueiry, Karen Gelmon, et al.
Clinical Colorectal Cancer|August 21, 2021
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal CancerKanan Alshammari, Kyaw L Aung, Tong Zhang, et al.
Pageof 19